Drug Trial Radar · NCT04820686
A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection
Last checked: Nov 19, 2026Latest source record: Nov 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
65
Actual
Start
May 7, 2021
Primary completion
Mar 30, 2023
Study completion Mar 30, 2023
Sponsor
- Lead sponsor
- Assembly BiosciencesIndustry
- Sponsor type
- Industry
- Collaborators
- Arbutus Biopharma Corporation
- First posted
- Mar 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if vebicorvir (VBR, ABI-H0731) in combination with AB-729 is safe and effective in participants with chronic hepatitis B infection (cHBV) receiving a standard of care nucleos(t)ide/reverse transcriptase inhibitor (SOC NrtI).
Conditions
- Chronic Hepatitis B
Interventions
VBRDrug
VBR is an HBV core protein inhibitor. Participants will receive VBR 300 mg tablets orally once daily (QD).
AB-729Drug
AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.
SOC NrtIDrug
Participants will receive their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With One or More Adverse Events (AEs)Time frame: AEs were collected from the time of signing the informed consent until the final follow-up visit, up to 96 weeks.
- Number of Participants With Premature Treatment Discontinuation Due to AEsTime frame: AEs were collected from the time of signing the informed consent until the final follow-up visit, up to 96 weeks.
- Number of Participants With One or More Abnormal Laboratory ResultTime frame: Laboratory results were collected from the time of signing the informed consent until the study was early terminated, up to 96 weeks.
Locations
20 sites in 4 countries. Site status is shown where the registry gives one.
Saint Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia
Saint George Hospital - Australia
Kogarah, New South Wales, Australia
Liverpool Hospital
Liverpool, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Footscray Hospital
Footscray, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Melbourne Health
Parkville, Victoria, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
Acibadem City Clinic Tokuda Hospital
Sofia, Bulgaria
University Multiprofile Hospital for Active Treatment St. Ivan Rilski
Sofia, Bulgaria
Nov Rehabilitatsionen Tsentar EOOD
Stara Zagora, Bulgaria
Diagnostic Consultative Center Aleksandrovska
Sofia, Sofia-Grad, Bulgaria
Centre Hospitalier Université de Québec - Université Laval
Québec, Canada
Vancouver Infectious Disease Centre
Vancouver, British Columbia, Canada
Pacific Gastroenterology Associates
Vancouver, British Columbia, Canada
University Hospital - London Health Sciences Centre
London, Ontario, Canada
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Toronto Liver Centre
Toronto, Ontario, Canada
Auckland Clinical Studies
Auckland, New Zealand
Wellington Regional Hospital
Wellington, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.